Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Daiichi Sankyo
Farmers Insurance
Baxter
Dow
Accenture
Federal Trade Commission
Deloitte
US Department of Justice

Generated: December 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ESZOPICLONE

« Back to Dashboard

Clinical Trials for Eszopiclone

Trial ID Title Status Sponsor Phase Summary
NCT00120250 Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder Completed Massachusetts General Hospital Phase 4 The purpose of this study is to obtain data investigating the safety and efficacy of eszopiclone for the treatment of post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with eszopiclone treatment on neuroendocrine correlates of PTSD. The investigators hypothesize that eszopiclone will be significantly more effective than placebo and well tolerated for PTSD-related sleep disturbance, improvement in sleep will be associated with improvement in overall PTSD symptoms, and patients with PTSD-related sleep disturbances will have abnormal levels of stress hormones.
NCT00167375 Testing the Nocturnal Sleep Latency Profile in Primary Insomnia Completed American Academy of Sleep Medicine Phase 1 This study tests a new kind of sleep study in which subjects are awakened 2 times after initially going to sleep. The study focuses on the EEG signal process as a person goes to sleep. The general hypothesis is that the signal properties are stable from night to night during baseline studies, and are different between controls and patients with primary insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia intervention. Then the new kind of study is repeated in the patients. The controls only are examined in baseline studies.
NCT00167375 Testing the Nocturnal Sleep Latency Profile in Primary Insomnia Completed Sunovion Phase 1 This study tests a new kind of sleep study in which subjects are awakened 2 times after initially going to sleep. The study focuses on the EEG signal process as a person goes to sleep. The general hypothesis is that the signal properties are stable from night to night during baseline studies, and are different between controls and patients with primary insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia intervention. Then the new kind of study is repeated in the patients. The controls only are examined in baseline studies.
NCT00167375 Testing the Nocturnal Sleep Latency Profile in Primary Insomnia Completed University of Pittsburgh Phase 1 This study tests a new kind of sleep study in which subjects are awakened 2 times after initially going to sleep. The study focuses on the EEG signal process as a person goes to sleep. The general hypothesis is that the signal properties are stable from night to night during baseline studies, and are different between controls and patients with primary insomnia. The primary insomnia patients then go on to have about 2 weeks of an insomnia intervention. Then the new kind of study is repeated in the patients. The controls only are examined in baseline studies.
NCT00235508 Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder Completed Sunovion Phase 4 To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an approved anxiolytic agent and will be randomized to nightly therapy with either eszopiclone or placebo.
NCT00247624 Improving Sleep and Psychological Functioning in People With Depression and Insomnia Unknown status National Institute of Mental Health (NIMH) Phase 4 This study will evaluate the safety and effectiveness of treatment with both a sleeping pill and antidepressant medication in improving sleep and psychological functioning in people with depression and insomnia.
NCT00247624 Improving Sleep and Psychological Functioning in People With Depression and Insomnia Unknown status Wake Forest University Phase 4 This study will evaluate the safety and effectiveness of treatment with both a sleeping pill and antidepressant medication in improving sleep and psychological functioning in people with depression and insomnia.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Eszopiclone

Condition Name

Condition Name for Eszopiclone
Intervention Trials
Insomnia 26
Primary Insomnia 10
Obstructive Sleep Apnea 5
Sleep Initiation and Maintenance Disorders 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Eszopiclone
Intervention Trials
Sleep Initiation and Maintenance Disorders 38
Sleep Apnea, Obstructive 7
Disease 7
Sleep Apnea Syndromes 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Eszopiclone

Trials by Country

Trials by Country for Eszopiclone
Location Trials
United States 274
Japan 24
United Kingdom 6
Ukraine 2
India 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Eszopiclone
Location Trials
Massachusetts 19
California 13
Pennsylvania 12
Ohio 11
New Jersey 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Eszopiclone

Clinical Trial Phase

Clinical Trial Phase for Eszopiclone
Clinical Trial Phase Trials
Phase 4 23
Phase 3 15
Phase 2/Phase 3 2
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Eszopiclone
Clinical Trial Phase Trials
Completed 48
Unknown status 3
Recruiting 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Eszopiclone

Sponsor Name

Sponsor Name for Eszopiclone
Sponsor Trials
Sunovion 34
Massachusetts General Hospital 5
Brigham and Women's Hospital 4
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Eszopiclone
Sponsor Trials
Industry 46
Other 42
NIH 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
US Army
Colorcon
Johnson and Johnson
Fish and Richardson
Deloitte
Baxter
Julphar
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.